# Ursolic acid alleviates liver injury in diabetic mice induced by high-fat diet combined with streptozotocin via the NLRP3 signaling pathway

**Authors:** Xinyan Wang, Ruyu Ma, Di Lou, Hanbing Li, Minyou Qi

PMC · DOI: 10.1371/journal.pone.0340643 · 2026-02-04

## TL;DR

Ursolic acid helps protect the liver in diabetic mice with fatty liver disease by reducing inflammation and oxidative stress through the NLRP3 pathway.

## Contribution

This study is the first to systematically investigate ursolic acid's protective effects in T2DM combined with NAFLD via the NLRP3 signaling pathway.

## Key findings

- Ursolic acid reduced hepatic lipid deposition and serum ALT/AST levels in diabetic mice.
- UA inhibited oxidative stress by increasing SOD, CAT, and GSH-Px activities in liver tissues.
- Ursolic acid suppressed NLRP3 inflammasome activation, reducing IL-1β and TGF-β1 expression.

## Abstract

Non-alcoholic fatty liver disease (NAFLD) is a type of metabolic stress-induced liver injury that is closely related to type 2 diabetes mellitus (T2DM). Ursolic acid (UA), a natural pentacyclic triterpenoid compound, has anti-inflammatory, hypoglycemic and liver-protective effects. However, its role in regulating liver injury through the NLRP3 inflammasome pathway in a T2DM combined with NAFLD model has not been systematically elucidated. This study systematically evaluated the protective effect of UA on NAFLD and its molecular mechanism through in vivo (STZ + high-fat diet-induced NAFLD mouse model) and in vitro (high glucose + palmitic acid-induced LO2 cell oxidative stress model) experiments. The results showed that UA significantly improved hepatic lipid deposition, reduced serum ALT/AST levels, and effectively alleviated oxidative stress, as indicated by decreased malondialdehyde (MDA) content and increased activities of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px) in liver tissues. Further mechanism studies revealed that UA could significantly down-regulate the expression levels of pro-inflammatory factor IL-1β and pro-fibrotic factor TGF-β1 by inhibiting NLRP3 inflammasome activation, and simultaneously reduce the deposition of type IV collagen. This study demonstrated that ursolic acid (UA) has a protective effect on T2DM combined with NAFLD, and its mechanism of action may be related to the regulation of the NLRP3 signaling pathway by UA, which inhibits oxidative stress, inflammation and fibrosis.

## Linked entities

- **Proteins:** NLRP3 (NLR family pyrin domain containing 3), IL1B (interleukin 1 beta), TGFB1 (transforming growth factor beta 1), SOD1 (superoxide dismutase 1), CAT (catalase), Gpx1 (glutathione peroxidase 1)
- **Chemicals:** ursolic acid (PubChem CID 64945), streptozotocin (PubChem CID 29327), palmitic acid (PubChem CID 985), malondialdehyde (PubChem CID 10964)
- **Diseases:** non-alcoholic fatty liver disease (MONDO:0013209), type 2 diabetes mellitus (MONDO:0005148)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Gpt (glutamic pyruvic transaminase, soluble) [NCBI Gene 76282] {aka 1300007J06Rik, 2310022B03Rik, ALT, ALT1, Gpt-1, Gpt1}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, Gapdh (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 14433] {aka Gapd}, Cat (catalase) [NCBI Gene 12359] {aka 2210418N07, Cas-1, Cas1, Cs-1}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, NLRP3 (NLR family pyrin domain containing 3) [NCBI Gene 114548] {aka AGTAVPRL, AII, AVP, C1orf7, CIAS1, CLR1.1}, IL18 (interleukin 18) [NCBI Gene 3606] {aka IGIF, IL-18, IL-1g, IL1F4}, Rhoa (ras homolog family member A) [NCBI Gene 11848] {aka Arha, Arha1, Arha2}, Glp1r (glucagon-like peptide 1 receptor) [NCBI Gene 14652] {aka GLP-1R, GLP1Rc}, Nlrp3 (NLR family, pyrin domain containing 3) [NCBI Gene 216799] {aka AGTAVPRL, AII/AVP, Cias1, FCAS, FCU, MWS}, CASP1 (caspase 1) [NCBI Gene 834] {aka ICE, IL1BC, P45}, Slc17a5 (solute carrier family 17 (anion/sugar transporter), member 5) [NCBI Gene 235504] {aka 4631416G20Rik, 4732491M05, AST, ISSD, NSD, SD}, Nox4 (NADPH oxidase 4) [NCBI Gene 50490], Rock1 (Rho-associated coiled-coil containing protein kinase 1) [NCBI Gene 19877] {aka 1110055K06Rik, Rock-I}, Cort (cortistatin) [NCBI Gene 12854] {aka CST, PCST}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, Tmprss11d (transmembrane protease, serine 11d) [NCBI Gene 231382] {aka AST, AsP}, Il1b (interleukin 1 beta) [NCBI Gene 16176] {aka IL-1beta, Il-1b}, Sts (steroid sulfatase) [NCBI Gene 20905] {aka ArsC}, Tgfb1 (transforming growth factor, beta 1) [NCBI Gene 21803] {aka TGF-beta1, TGFbeta1, Tgfb, Tgfb-1}, SOD1 (superoxide dismutase 1) [NCBI Gene 6647] {aka ALS, ALS1, HEL-S-44, IPOA, SOD, STAHP}
- **Diseases:** obesity (MESH:D009765), NASH (MESH:D005235), hyperlipidemia (MESH:D006949), liver injury (MESH:D017093), sarcopenia (MESH:D055948), chronic hyperglycemia (MESH:D006943), hypertension (MESH:D006973), sleep apnoea (MESH:D012891), T2DM (MESH:D003924), lipid (MESH:D011017), fibrosis (MESH:D005355), cancers (MESH:D009369), hepatic fibrosis (MESH:D008103), lethargy (MESH:D053609), fatty degeneration (MESH:D008067), non-hepatic malignancies (MESH:D016751), diabetes (MESH:D003920), NAFLD (MESH:D065626), MS (MESH:D024821), insulin resistance (MESH:D007333), neurological disorders (MESH:D009461), cardiovascular and renal complications (MESH:D002318), liver disease (MESH:D008107), Hepatic injury (MESH:D056486), pain (MESH:D010146), coronary artery disease (MESH:D003324), dislocation (MESH:D004204), chronic kidney disease (MESH:D051436), adiposity (MESH:D018205), hepatic steatosis (MESH:D005234), hyperglycemic (MESH:D006944), dyslipidemia (MESH:D050171), metabolic disorders (MESH:D008659), weight gain (MESH:D015430), hepatic inflammation (MESH:D007249)
- **Chemicals:** SDS (MESH:D012967), Alexa Fluor 488 (MESH:C000711379), Lipid (MESH:D008055), DAPI (MESH:C007293), glucose (MESH:D005947), DAB (-), citrate (MESH:D019343), triterpenoid (MESH:D014315), fat (MESH:D005223), free fatty acids (MESH:D005230), DC (MESH:D003841), DMSO (MESH:D004121), UA (MESH:C005466), dip (MESH:C067227), ethanol (MESH:D000431), EDTA (MESH:D004492), Triton X-100 (MESH:D017830), paraformaldehyde (MESH:C003043), mannitol (MESH:D008353), ice (MESH:D007053), H&amp;E (MESH:D006371), PVDF (MESH:C024865), ROS (MESH:D017382), cisplatin (MESH:D002945), eosin (MESH:D004801), STZ (MESH:D013311), 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MESH:C022616), Oil Red O (MESH:C011049), sodium pentobarbital (MESH:D010424), cholesterol (MESH:D002784), blood glucose (MESH:D001786), hematoxylin (MESH:D006416), CO2 (MESH:D002245), MTT (MESH:C070243), paraffin (MESH:D010232), PBS (MESH:D007854), H2O2 (MESH:D006861), H2O (MESH:D014867), isoflurane (MESH:D007530), saline (MESH:D012965), PA (MESH:D019308), oil (MESH:D009821), MDA (MESH:D008315), TG (MESH:D014280)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116], Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** LO2 — Homo sapiens (Human), Amelanotic melanoma, Cancer cell line (CVCL_C7SD), C57BL/6J — Mus musculus (Mouse), Transformed cell line (CVCL_C0MW), /6J — Homo sapiens (Human), Cutaneous melanoma, Cancer cell line (CVCL_W797)

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12871989/full.md

---
Source: https://tomesphere.com/paper/PMC12871989